Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi provides u pdate on amcenestrant clinical development program

Press Release: Sanofi provides update on amcenestrant clinical development program

GlaxoSmithKline

Haleon PLC

Johnson & Johnson

Pfizer

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

Potential Lawsuits Causing Zantac Manufacturers Heartburn

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Sanofi SA ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY

Investors are bracing for billions of dollars in losses due to lawsuits filed over the heartburn drug Zantac.

Zantac Lawsuits Tank Pharma Stocks As Haleon, GSK, Sanofi Issue Defense

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.

Drugmaker stocks slammed over Zantac lawsuit concerns

After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer. A J.P. Morgan note also called the selloff overdone.

GSK and Sanofi Push Back on Zantac Worries. Shares Rebounded.

READING, England--(BUSINESS WIRE)--First patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide

NIHR and Sanofi Announce First Patient Enrolled in Large European Clinical Study to Investigate Protection Against RSV, the Leading Cause of Infant Hospitalisation Worldwide

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

Sanofi SNY, -3.94% SAN, +0.25% was upgraded to hold from sell at Deutsche Bank, after the heavy selling over the previous two days on worries about Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22.

Sanofi upped to hold at Deutsche Bank as Zantac fears make a sell 'egregious'

European shares eked out gains on Friday at the open after Sanofi and GSK led a rebound in healthcare stocks, with the main STOXX 600 index set for weekly gains.

European shares eke out gains at open as healthcare stocks rebound

Source: Willy Barton / Shutterstock.com Investors in GSK (NYSE: GSK ) stock, Pfizer (NYSE: PFE ) and Sanofi (NASDAQ: SNY ) are all feeling the heat today. Reportedly, they're concerned about legal possibilities surrounding Zantac, a heartburn drug removed from stores in 2019 due to safety concerns.

GSK, PFE, SNY Stocks Fall on Zantac Litigation

Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms appeared first on Investor's Business Daily.

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms

European-listed shares of drugmakers Haleon HLN, -11.81% , GSK GSK, -8.48% and Sanofi SAN, -8.81% plunged on Thursday on worries over the Zantac heartburn medication litigation. The first trial is set to begin on Aug. 22.

GSK, Sanofi and Haleon slump on worries over Zantac litigation

Innovent Biologics Inc said on Friday Paris-based Sanofi SA would invest HK$2.42 billion ($307.88 million) in the biopharmaceutical group to jointly develop two cancer drugs in China.

China's Innovent Biologics secures over $300 million investment from Sanofi

Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China

Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent solid tumors in China Sanofi to make an initial equity investment of €300 million in Innovent in addition to the strategic multi-product collaboration This strategic partnership demonstrates Innovent and Sanofi's commitment to bringing high quality oncology medicines to patients in China SAN FRANCISCO and SUZHOU, China , Aug 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Sanofi announced a collaboration to bring innovative medicines to patients in China with difficult-to-treat cancers. Both companies are committed to accelerating the development and commercialization of two Sanofi key clinical stage oncology assets: Phase III SAR408701 (tusamitamab ravtansine; anti-CEACAM5 antibody-drug conjugate) and Phase II SAR444245 (non-alpha IL-2), combining with sintilimab, the leading checkpoint inhibitor in China.

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

BRIDGEWATER, N.J. , Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses.

Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi SA ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

I am bullish on Sanofi as I see the company undervalued as compared to both the company's financials and competitors (EU pharma peers). Sanofi is a leading global pharmaceutical company, with strong research and innovation capabilities.

Sanofi: Arguably One Of The Most Undervalued Pharma Stocks

Sanofi SA (NASDAQ:SNY ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Jean-Baptiste de Chatillon - EVP & CFO Bill Sibold - EVP, Sanofi Genzyme and President, Sanofi North America John Reed - EVP & Global Head, Research & Development Thomas Triomphe - Head, Vaccines Olivier Charmeil - EVP, General Medicines Julie Van Ongevalle - EVP, Consumer Healthcare Conference Call Participants Wimal Kapadia - Sanford C. Bernstein Jo Walton - Crédit Suisse Graham Parry - Bank of America Securities Richard Vosser - J.P.

Sanofi SA (SNY) CEO Paul Hudson on Q2 2022 Results - Earnings Call Transcript

Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines.

Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View

Sanofi stock fell early Thursday despite a major pop in sales of Dupixent, its blockbuster eczema and asthma treatment. The post Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain appeared first on Investor's Business Daily.

Sanofi Ekes Out Narrow Beat As Eczema Giant Scores Massive Gain

French healthcare group Sanofi lifted its full-year earnings outlook on continued strong sales growth for its bestselling drug Dupixent.

Sanofi lifts profit outlook as Dupixent sales surge over 43%

CAMBRIDGE, Mass. , July 26, 2022 /PRNewswire/ -- As part of its ongoing efforts to address disparities in underrepresented communities, Sanofi has announced a collaboration with Howard University College of Pharmacy for a two-year post-professional Doctorate in Pharmacy fellowship program.

News for Sanofi Stock (SNY)